Foresite Capital Management Iv, LLC Syndax Pharmaceuticals Inc Transaction History
Foresite Capital Management Iv, LLC
- $153 Million
- Q3 2024
A detailed history of Foresite Capital Management Iv, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Foresite Capital Management Iv, LLC holds 875,000 shares of SNDX stock, worth $12.3 Million. This represents 11.01% of its overall portfolio holdings.
Number of Shares
875,000
Previous 875,000
-0.0%
Holding current value
$12.3 Million
Previous $18 Million
6.24%
% of portfolio
11.01%
Previous 12.07%
Shares
2 transactions
Others Institutions Holding SNDX
# of Institutions
231Shares Held
90MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$111 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$81.8 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$69.8 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$68.4 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$57.5 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $792M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...